Anteris Technologies initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $16 price target The firm believes the company’s DurAVR combines the best attributes of Edwards’ Sapien 3 and Medtronic’s Evolut transcatheter aortic valve replacement devices. This should drive “significant share capture” for Anteris upon FDA approval, the analyst tells investors in a research note. Wells says the TAVR market is large and growing.